SITC 2022 Poster 199

3D Ex vivo Patient Tissue Platform for Immuno-Oncology Drug Testing

Nataliia Beztsinna, Sander Basten, Fanny Grillet, Niels Meesters, Donny van der Meer, Kuan Yan, Emma Spanjaard, Willemijn Vader, Leo Price

Many immuno-oncology drugs fail in clinical trials (about 90%), which is partly due to the lack of in vitro and in vivo models that sufficiently recapitulate the tumor microenvironment (TME). In effect, immunotherapy has not revealed its estimated potential, demonstrated by low response rates in the clinics (about 20%), when treating cancer patients. To bridge the gap in translational model systems, a 3D ex vivo patient tissue platform was developed which uses 3D ex vivo tumor cultures, where tumor endogenous cells of the TME are preserved, this tumor immune context can include (exhausted) tumor infiltrating lymphocytes (TILs).

These TME components accurately replicate the immunological complexity in the tumor, and partake in affecting tumor drug responses. The readout from this 3D Ex vivo Patient Tissue platform is generated with high content image (HCI)-based analysis that provides a quantification of ex vivo tumor responses These advanced preclinical models preserve potentially novel targets for drug development, making them a crucial component to be presented upon drug efficacy evaluations. This can eventually enhance clinical trial success rate and improve clinical impact of current and future immunotherapies.

Download this Poster to Discover:

• How the 3D ex vivo patient tissue platform offers a rapid, reliable and patient-relevant approach to test preclinical drug candidate
  
  
• Potential to significantly improve the preclinical evaluation of drugs targeting the tumor and/or TME
  
  
• HCI-based analysis of the response to the various treatments

Download the Poster Now!